News | April 25, 2026
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Angelique Kruif brings over 20 years of HR leadership built across a range of international organisations
With a PhD in Biochemistry and an executive MBA, she brings nearly two decades of experience in the in vitro diagnostics (IVD) sector
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Subscribe To Our Newsletter & Stay Updated
